[ad_1]
Pharmaceutical company Eli Lilly on Wednesday asked the U.S. health regulator to authorize its antibody monotherapy for Covid-19 in an emergency procedure, with the intention of seeking similar approval next month for a combination therapy with two. of your medications. antibodies, Reuters reports.
Also read: BREAKING – RECORD of new cases of Covid-19, in the last 24 hours: 2958
The drugmaker announced on Wednesday positive data from an intermediate-phase clinical study on a combination therapy with antibodies, which helped reduce hospitalization periods and emergency visits for Covid-19 patients, News.ro reports.
The data are consistent with results from a September clinical trial that tested a single antibody treatment called LY-CoV555.
Several drug manufacturers are testing antibody treatments for Covid-19 patients, with the goal of preventing the progression of symptoms.
Neither of these drugs is licensed for emergency use in the United States, but an experimental combination of two antibodies being developed by Regeneron Pharmaceuticals is among President Donald Trump’s treatments for his Covid-19 infection.
Eli Lilly expects 100,000 doses of LY-CoV555 to be available in October and around 1 million doses in the fourth quarter. Eli Lilly estimates that she will administer 50,000 doses of combination therapy in the fourth trimester.
[ad_2]
